Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MERTK | Q12866 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12214423 | 0.89 | EGFR (0.47) | EGFRERBB2METKDRMERTK | |
| SCHEMBL1018220 | 0.89 | EGFR (0.49) | EGFRERBB2METKDRMERTK | |
| SCHEMBL26035579 | 0.85 | NPC1 (0.55) | MAPK14KMT2ANPC1RAB9A | |
| SCHEMBL26037249 | 0.84 | NPC1 (0.50) | MAPK14KMT2ANPC1RAB9A | |
| SCHEMBL26038384 | 0.83 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL26037260 | 0.81 | MAPK14 (0.48) | MAPK14KMT2ANPC1RAB9A | |
| SCHEMBL26035597 | 0.81 | MAPK14 (0.46) | MAPK14KMT2ANPC1RAB9A | |
| SCHEMBL26035489 | 0.81 | ATM (0.55) | MAPK14KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL26035569 | 0.80 | CREBBP (0.47) | MAPK14KMT2ANPC1RAB9A | |
| SCHEMBL26035561 | 0.80 | MAPK14 (0.47) | MAPK14KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPK14 698/4885EGFR 7/4885ERBB2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.